RT Journal Article
SR Electronic
T1 ERS task force statement: diagnosis and treatment of primary spontaneous pneumothorax
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 321
OP 335
DO 10.1183/09031936.00219214
VO 46
IS 2
A1 Jean-Marie Tschopp
A1 Oliver Bintcliffe
A1 Philippe Astoul
A1 Emilio Canalis
A1 Peter Driesen
A1 Julius Janssen
A1 Marc Krasnik
A1 Nicholas Maskell
A1 Paul Van Schil
A1 Thomy Tonia
A1 David A. Waller
A1 Charles-Hugo Marquette
A1 Giuseppe Cardillo
YR 2015
UL http://erj.ersjournals.com/content/46/2/321.abstract
AB Primary spontaneous pneumothorax (PSP) affects young healthy people with a significant recurrence rate. Recent advances in treatment have been variably implemented in clinical practice. This statement reviews the latest developments and concepts to improve clinical management and stimulate further research.The European Respiratory Society's Scientific Committee established a multidisciplinary team of pulmonologists and surgeons to produce a comprehensive review of available scientific evidence.Smoking remains the main risk factor of PSP. Routine smoking cessation is advised. More prospective data are required to better define the PSP population and incidence of recurrence. In first episodes of PSP, treatment approach is driven by symptoms rather than PSP size. The role of bullae rupture as the cause of air leakage remains unclear, implying that any treatment of PSP recurrence includes pleurodesis. Talc poudrage pleurodesis by thoracoscopy is safe, provided calibrated talc is available. Video-assisted thoracic surgery is preferred to thoracotomy as a surgical approach.In first episodes of PSP, aspiration is required only in symptomatic patients. After a persistent or recurrent PSP, definitive treatment including pleurodesis is undertaken. Future randomised controlled trials comparing different strategies are required.A European Task Force reviews scientific evidence and suggests future research for primary spontaneous pneumothorax http://ow.ly/MWhuF